ABEONA THERAPEUTICS INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $837.0K | $889.0K | $1.0M | $925.0K | $2.0M | $4.4M | $1.8M |
| Cost of Revenue | — | — | — | — | $0 | $125.0K | $267.0K | $148.0K |
| Gross Profit | — | — | — | — | $925.0K | $1.9M | $4.1M | $1.7M |
| Gross Margin | — | — | — | — | 100.0% | 93.9% | 93.9% | 92.0% |
| Operating Expenses | ||||||||
| Research & Development | $38.7M | $17.0M | $10.7M | $4.7M | $333.0K | $884.0K | $2.0M | $3.6M |
| SG&A Expense | $20.1M | $10.9M | $13.3M | $14.3M | $3.7M | $4.8M | $6.0M | $5.8M |
| Operating Income | $-58.2M | $-27.8M | $-23.9M | $-18.5M | $-3.1M | $-3.8M | $-4.3M | $-7.9M |
| Operating Margin | -1,940.2% | -3,325.7% | -2,686.3% | -1,783.3% | -338.5% | -186.3% | -98.0% | -428.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | $-10.5M | $-2.5M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $17.0K |
| Net Income | $-56.7M | $-27.3M | $-21.9M | $-14.5M | $-26.8M | $4.4M | $-10.5M | $-2.5M |
| Net Margin | -1,890.3% | -3,263.9% | -2,460.4% | -1,396.7% | -2,894.9% | 217.9% | -239.1% | -137.7% |
| EPS (Basic) | $-0.40 | $-0.22 | $-0.21 | $-0.18 | $-0.36 | $0.02 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.40 | $-0.22 | $-0.21 | $-0.18 | $-0.36 | $0.02 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 143.8M | 140.7M | 102.5M | 82.8M | 81.6M | 84.8M | 4.06B | — |
| Shares Outstanding (Diluted) | 143.8M | 140.7M | 102.5M | 82.8M | 81.6M | 85.6M | 4.06B | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |